If you are interested in learning more about this study, please call or email the contact person below
|Title||EVarQuit: Extended pre-quit varenicline to assist in quitting smoking|
|Description||Varenicline (Chantix®) is the best quit smoking medication available, but even with varenicline more than half of people return to smoking within 6 months. The main purpose of this clinical research study is to definitively determine whether extended pre-quit varenicline makes it easier to quit and stay quit.
Participants will be in this research study for approximately 6 months, with active treatment for the first four months and a follow-up visit at 6 months
The research will be conducted at the University at Buffalo South Campus, Diefendorf Hall.
If you're interested in this study, please contact the study coordinator listed below.
|Objective||We aim to improve smoking cessation rates obtained with varenicline, the best quit smoking agent available, by a simple but theory-based manipulation: increasing the duration of pre-quit varenicline treatment from 1 to 4 weeks.
Keywords: Smoking, smoking cessation, addiction
|Principal Investigator||HAWK, LARRY|
|Key Eligibility||Ages 18-70
Smoking at least 10 cigarettes per day for the last 6 months
Moderately motivated to quit smoking
|Disease Group||Other; Substance Abuse/Addictions|